Aduro Biotech, Inc. (ADRO) Receives Average Recommendation of “Buy” from Analysts

Aduro Biotech, Inc. (NASDAQ:ADRO) has been assigned an average rating of “Buy” from the seven analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $20.00.

A number of research analysts have commented on the company. Canaccord Genuity set a $30.00 price objective on Aduro Biotech and gave the company a “buy” rating in a research report on Thursday, March 2nd. Roth Capital reiterated a “buy” rating and issued a $17.00 price objective on shares of Aduro Biotech in a research report on Tuesday, March 7th. FBR & Co reissued a “buy” rating and issued a $23.00 price target on shares of Aduro Biotech in a research note on Tuesday, March 7th. Zacks Investment Research downgraded Aduro Biotech from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 2nd. Finally, HC Wainwright assumed coverage on Aduro Biotech in a research note on Monday, May 1st. They issued a “buy” rating and a $18.00 price target on the stock.

In other news, insider Stephen T. Isaacs sold 27,273 shares of the stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $10.28, for a total value of $280,366.44. Following the transaction, the insider now owns 129,473 shares of the company’s stock, valued at approximately $1,330,982.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Thomas W. Dubensky sold 144,301 shares of the stock in a transaction on Monday, June 5th. The shares were sold at an average price of $10.03, for a total value of $1,447,339.03. Following the completion of the transaction, the insider now directly owns 117,871 shares in the company, valued at approximately $1,182,246.13. The disclosure for this sale can be found here. In the last three months, insiders sold 250,478 shares of company stock worth $2,519,178. 6.60% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of ADRO. Goldman Sachs Group Inc. increased its position in Aduro Biotech by 330.5% in the first quarter. Goldman Sachs Group Inc. now owns 236,721 shares of the biotechnology company’s stock worth $2,545,000 after buying an additional 181,734 shares during the period. Tudor Investment Corp ET AL increased its position in Aduro Biotech by 34.8% in the first quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock worth $166,000 after buying an additional 3,984 shares during the period. Highbridge Capital Management LLC bought a new position in Aduro Biotech during the first quarter worth $853,000. Schwab Charles Investment Management Inc. increased its position in Aduro Biotech by 5.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 145,112 shares of the biotechnology company’s stock worth $1,560,000 after buying an additional 7,812 shares during the period. Finally, Renaissance Technologies LLC increased its position in Aduro Biotech by 762.1% in the first quarter. Renaissance Technologies LLC now owns 181,900 shares of the biotechnology company’s stock worth $1,955,000 after buying an additional 160,800 shares during the period. 35.68% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Aduro Biotech, Inc. (ADRO) Receives Average Recommendation of “Buy” from Analysts” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2654825/aduro-biotech-inc-adro-receives-average-recommendation-of-buy-from-analysts.html.

Aduro Biotech (NASDAQ ADRO) opened at 10.50 on Tuesday. Aduro Biotech has a 52-week low of $8.75 and a 52-week high of $16.43. The firm’s market cap is $734.09 million. The company’s 50-day moving average price is $10.13 and its 200-day moving average price is $10.70.

Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings data on Tuesday, May 2nd. The biotechnology company reported ($0.32) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.07. The firm had revenue of $3.77 million for the quarter, compared to analyst estimates of $3.74 million. Aduro Biotech had a negative return on equity of 35.35% and a negative net margin of 166.85%. Analysts predict that Aduro Biotech will post ($1.39) EPS for the current year.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ADRO”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.